Region-specific biomarkers FGFR4, FLT1, and WNT5A are linked to tumor behavior and therapeutic response in CRC. Comprehensive genomic profiling (CGP) aids in precision medicine by identifying genetic ...

IPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial ...

The Foundation for the National Institutes of Health (FNIH) announces that the Food and Drug Administration (FDA) has qualified the treatment-related change in hip bone mineral density (BMD) as a ...

Boston-based Beth Israel Deaconess Medical Center played a role in a new FDA decision that allows bone mineral density, measured through noninvasive imaging, to serve as a qualified endpoint in ...

Precision oncology advancements have led to new treatment options for gastric cancer, including immunotherapy and targeted ...

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, ...

The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer. Physicians can use the test to ...

TUCSON, Ariz. March 6, 2025 — Critical Path Institute ® (C-Path) and Boston Medical Center (BMC) published results for six biomarkers that could improve the early and accurate detection of kidney ...

The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...